Silverarc Capital Management »

Urogen Pharma shares owned by Silverarc Capital Management

Quarter-by-quarter ownership of Urogen Pharma (URGN) shares owned by Silverarc Capital Management from 13F filings

Historical chart of Silverarc Capital Management investment in Urogen Pharma

Tip: Access up to 7 years of quarterly data

All positions including Urogen Pharma held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Urogen Pharma by Silverarc Capital Management

Quarter filed Position value Share count Share price at filing
2023-09-30 $7.1M 509k 14.01

More positions owned by Silverarc Capital Management

ImmunoGen Long Option Calls Call Option
SPRD S&P Biotech ETF Long Option Calls Call Option (XBI)
Akero Therapeutics Long Option Calls Call Option (AKRO)
Mirati Therapeutics Long Option Calls Call Option
Morphic Holding Equities (MORF)
Merus NV Equities (MRUS)
CymaBay Therapeutics Long Option Calls Call Option
Soleno Therapeutics Equities (SLNO)
Intra-Cellular Therapies Equities (ITCI)
Poseida Therapeutics Equities (PSTX)
Krystal Biotech Equities (KRYS)
Mersana Therapeutics Long Option Calls Call Option (MRSN)
KalVista Pharmaceuticals Long Option Calls Call Option (KALV)
Biogen Idec Equities (BIIB)
Urogen Pharma Equities (URGN)

View all positions for Silverarc Capital Management

Top funds holding Urogen Pharma

RA Capital Management
Dr. Jeffrey R. Jay, M.D.
Credit Suisse
Harel Insurance Investments & Financial Services
Migdal Insurance & Financial Holdings
Millennium Management
Opaleye Management
Superstring Capital Management
Laurion Capital Management
Wells Fargo & Company
Citadel Advisors
Vanguard Group
ARK Investment Management
AlphaCentric Advisors
Schonfeld Strategic Advisors

View all funds holding Urogen Pharma